Envoy Medical, Inc.

Sep 22, 2026

Envoy Medical Announces New Patents, Further Expanding Global Patent Portfolio

Envoy Medical has announced the grant of two new international patents, increasing its patent portfolio to 97. The patents support the company's innovative approach to fully implanted hearing devices. CEO Brent Lucas highlighted the importance of their intellectual property strategy in differentiating the company in the hearing health market. The Acclaim Cochlear Implant, currently under investigation, is noted for its unique design leveraging the ear's natural anatomy.

Sep 2, 2026

Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th

Envoy Medical, a company specializing in hearing health, announced that its CEO, Brent Lucas, will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The presentation will highlight the company's innovative hearing solutions, including the Acclaim Cochlear Implant, which has received FDA Breakthrough Device Designation. The presentation will be available on demand for 90 days post-conference.

Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device

Envoy Medical has submitted the first module of its Modular Premarket Approval application to the FDA for its Breakthrough Device-designated cochlear implant. This modular approach allows for earlier FDA engagement and iterative feedback, reducing regulatory risks. The company plans to submit a total of four modules, with the final one expected in Q2 2027, providing investors with visibility into progress.

Jun 25, 2026

▲ +6.7%on this news· ran to +26% by day 3shared move

Envoy Medical Terminates At-the-Market (ATM) Equity Facility

Envoy Medical has terminated its at-the-market equity facility, reflecting its confidence in its current capital position. The company, known for its innovative hearing solutions, had previously authorized the sale of up to $15 million in shares. This decision is seen as a positive step towards strengthening its financial standing as it continues to develop unique hearing devices.

Jun 18, 2026

Envoy Medical to Present at Investor Conferences on June 25th

Envoy Medical Inc. (NASDAQ: COCH) will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026. CEO Brent Lucas will discuss the company's innovative fully implanted hearing solutions, including the Esteem and Acclaim cochlear implants. The Acclaim CI is designed for severe to profound sensorineural hearing loss and has received FDA Breakthrough Device Designation.

Jun 4, 2026

Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th

Envoy Medical Inc. (NASDAQ: COCH) will present at the Planet MicroCap Conference in Las Vegas from June 16-18, 2026. CEO Brent Lucas will speak on June 17 at 11:00 A.M. PT. The company will also hold one-on-one investor meetings during the event. Envoy Medical focuses on innovative hearing solutions, including the Esteem and Acclaim cochlear implants.

May 11, 2026

Envoy Medical Reports Landmark Accomplishments, FDA Approval of First-Of-Its-Kind Fully Implanted Cochlear Implant

Envoy Medical has announced significant progress in advancing its investigational Acclaim cochlear implant towards FDA approval. The company successfully completed enrollment in its pivotal clinical trial, an important milestone for achieving market entry. Additionally, Envoy has raised up to $78 million in financing, further strengthening its resources for commercialization. Promising initial clinical data indicates improvements in patient outcomes, bolstering confidence in the product's potential.

Mar 23, 2026

Envoy Medical Reports Full Year 2025 Financial Received FDA approval to expand fully implanted Acclaim Cochlear Implant Pivotal Clinical Trial to final stage

Envoy Medical reported its financial results for 2025, highlighting significant achievements including FDA approval to expand its pivotal clinical trial for the Acclaim cochlear implant. The company successfully raised capital and strengthened its balance sheet by eliminating $32 million in debt. This progress sets a positive outlook for 2026, as Envoy continues to gather data and prepare for a PMA submission to the FDA. Additionally, Envoy aims to enhance global patent protection for its hearing technology innovations.

Envoy Medical Regains Compliance with Nasdaq

Envoy Medical Inc. has officially regained compliance with Nasdaq listing requirements, following a notice of non-compliance issued in February 2025. The company implemented effective strategic financing initiatives that significantly strengthened its balance sheet. Following these changes, Envoy Medical is now positioned to maintain its listing on the Nasdaq Capital Market under the symbol 'COCH'. The company is focused on providing innovative hearing health solutions, including their fully implanted devices for hearing loss.

Envoy Medical Announces Closing of Up to $78.0 Million Upsized Public Offering

Envoy Medical Inc. announced the successful closing of a $78 million upsized public offering, securing $30 million upfront and up to $48 million from milestone-linked warrants. This financing aims to extend the company's cash runway into 2027, well beyond their expected PMA submission timeline. The offering was anchored by Nantahala Capital and saw participation from existing shareholder Glen Taylor and several healthcare funds. The funds raised will primarily support the company's operations and pivotal clinical studies for their Acclaim cochlear implant, which is currently in development.

Jan 29, 2026

Envoy Medical to Present at the Small Cap Growth Virtual Investor Conference February 5

Envoy Medical Inc. announced its participation in the Small Cap Growth Virtual Investor Conference scheduled for February 5, 2026. During the event, company management will discuss their innovative hearing solutions and answer investor queries in real time. Attendees unable to join live can access a recording afterward. Envoy Medical is known for its pioneering work in fully implanted hearing devices, including the Esteem active middle ear implant and the investigational Acclaim cochlear implant.

Dec 16, 2025

INVESTOR PRESENTATION DECEMBER 2025 www.envoymedical.com NASDAQ: COCH Hear for Life Nasdaq: COCH 2 FORWARD LOOKING STATEMENTS This presentation includes "forward - looking statements" within the meaning of the "safe harb

Envoy Medical presented its investment highlights, focusing on the Acclaim CI, the first fully implanted cochlear implant aimed at transforming the hearing health market. The company is currently in the late stages of development, with pivotal trials expected to be completed by Q1 2026. The presentation emphasized the potential market size of $84 billion in the U.S. for cochlear implants and highlighted the distinct features of the Acclaim CI, which are designed to improve the user experience significantly.

Dec 2, 2025

Envoy Medical Announces the Grant of Its 40th U.S. Patent

Envoy Medical has announced the grant of its 40th active U.S. patent, enhancing its intellectual property portfolio which includes 45 foreign patents. The new patent covers technology for cochlear implant systems that improve performance and reliability. The Acclaim cochlear implant, which received Breakthrough Device Designation from the FDA, is currently being tested in a pivotal clinical trial.

Nov 10, 2025

Envoy Medical Reports Third Quarter 2025 Financial and Operational Results

Envoy Medical reported a transformative third quarter for 2025, significantly improving its position by eliminating $32 million in debt and receiving FDA approval to expand its pivotal clinical trial. The company successfully enrolled the first three patients in this final stage and expanded its patent portfolio with several new global patents. Additionally, they announced a direct offering aimed at raising up to $16 million. These advancements position Envoy Medical favorably in the hearing health market amidst their ongoing clinical efforts.

Oct 27, 2025

Envoy Medical Receives Positive Listing Determination

Envoy Medical, Inc. (NASDAQ: COCH) announced that it has received a positive listing determination from the Nasdaq Hearings Panel, allowing for continued listing on the stock market. This decision is underpinned by notable factors such as improved stockholders' equity following recent capital raises and the progression of the Acclaim cochlear implant into its final clinical trial phase. The company now has until February 23, 2026, to demonstrate full compliance with Nasdaq Listing Rule 5550(b)(2). Envoy Medical has highlighted an increase in investor interest, with trading volumes rising post-trial announcement.

Oct 23, 2025

Envoy Medical to Present at the Virtual Technology Investor Conference on October 28th

Envoy Medical, a company specializing in innovative fully implanted hearing solutions, is set to present at the Virtual Technology Investor Conference on October 28, 2025. CEO Brent Lucas will lead the presentation, which aims to update investors on the company's progress and developments. Recently, Envoy Medical received FDA approval to move its pivotal clinical trial to the final stage and has secured multiple global patents for its cochlear implant technology. Additionally, the company closed a $16 million direct offering, demonstrating strong investor support.

Envoy Medical Announces Up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules $4 million upfront with up to additional $12 million of potential aggregate gross proceeds upon the exercise in

Envoy Medical, a hearing health company, announced a registered direct offering priced at-the-market under Nasdaq rules, aiming to raise up to $16 million. The plan includes selling approximately 3 million shares at $1.33 each, alongside unregistered warrants that could generate an additional $12 million if exercised. The proceeds will support working capital and general corporate needs. The offering is expected to close by October 9, 2025, subject to standard closing conditions.

Oct 7, 2025

▲ +97.1%on this newsshared move

Envoy Medical Receives FDA Approval to Advance its Pivotal Clinical Trial to Final Stage Based on Submission of Promising Three-Month Data

Envoy Medical has received FDA approval to advance its pivotal clinical trial for the fully implanted Acclaim cochlear implant to the final stage. The approval, based on promising three-month data from the first 10 patients, enables the company to shorten its timeline to commercialization by three to six months while also reducing anticipated capital needs by $10-$15 million. The trial will expand to include an additional 46 participants across seven sites, with indications of high interest in the investigational device. This advancement positions Envoy Medical to redefine industry standards in cochlear implants.

Envoy Medical Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules White Bear Lake, Minnesota

Envoy Medical Inc. announced a registered direct offering of 1,908,402 shares of its Class A common stock for $1.31 per share, generating estimated proceeds of $2.5 million. Additionally, the company is issuing unregistered warrants that could provide up to $7.5 million more upon exercise. The offering is set to close around September 23, 2025, pending customary conditions. Funds from the offering will be used for working capital and corporate purposes, although there are risks associated with the warrants potentially expiring unexercised.

Sep 19, 2025